New insights into clinical strategies for acute coronary syndrome based on biomarker-driven multiomics research

With rapid advancements in genomics, proteomics, and metabolomics researchers have gained significant insights into ACS (ACS) pathogenesis. Studies have revealed specific biomarkers linked to ACS and provided novel tools for risk evaluation and early diagnosis. Genomic breakthroughs have enabled exploration of genetic factors contributing to ACS. Transcriptomics has facilitated the analysis of gene expression alterations in patients with ACS. Proteomics has identified potential therapeutic targets by pinpointing biomarkers, paving the way for new drug development. Advances in metabolomics have enabled monitoring of changes in metabolic pathways, offering valuable information for early diagnosis and disease prognosis. In summary, multiomics research has shed light on the critical aspects of ACS clinical strategies, facilitating advancements in early diagnosis, risk assessment, and personalized therapy, and will increasingly assume a pivotal role in future clinical practice.